Division of Nestle SA
Latest From Galderma SA
New OTC medicines for fungal nail infections and verrucas have been launched in the UK by Galderma, Reckitt Benckiser and Vemedia, while new foot-care products have also been introduced by Blistex, Epitact and Dermatonics.
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.
Acne treatment study found set out to better understand the pathogenesis of pre-adolescent acne and the impact of OTC acne drug benzoyl peroxide after an earlier study showed treatment with ingredient significantly decreased alpha diversity on girls' skin.
A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Nestle SA
- Senior Management
Humberto C Antunes, CEO
John Dickinson, VP, CFO
Gabriel Villada, VP, Mktg. & Bus. Dev.
- Contact Info
Phone: (33) 1 58 86 45 45
Avenue Gratta-Paille 2
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.